We demonstrate manipulation of IL-13 signaling and response pathways via small-molecule inhibition {pan c-Jun N-terminal kinases [Janus kinase (JAK)] inhibitor} of STAT phosphorylation as a possible therapeutic target to down regulate myofibroblast differentiation and activity in Dupuytren’s disease. The gene discussed is IL13; the disease is Dupuytren Contracture.